Normal view

Received — 26 March 2026 ⏭ Nature Medicine

Nature Medicine
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study Ning An · Di Wang · Peiling Zhang · Jishuai Zhang · Philippe Parone · Jianlin Hu · Yuhan Bao · Li Xu · Haitao Ruan · Ying Wan · Xinyu Wen · Yang Gao · Chunrui Li
Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04244-6In a phase 1 trial, the in vivo generation of anti-BCMA CAR-T cells by lentiviral delivery was feasible and did not lead to dose-limiting toxicities in five patients with relapsed or refractory multiple myeloma.
25 March 2026 at 08:00

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study

By: Ning An · Di Wang · Peiling Zhang · Jishuai Zhang · Philippe Parone · Jianlin Hu · Yuhan Bao · Li Xu · Haitao Ruan · Ying Wan · Xinyu Wen · Yang Gao · Chunrui Li

25 March 2026 at 08:00

Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04244-6

In a phase 1 trial, the in vivo generation of anti-BCMA CAR-T cells by lentiviral delivery was feasible and did not lead to dose-limiting toxicities in five patients with relapsed or refractory multiple myeloma.